Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ovarian cancer screening.

Nicole Urban1, Martin W McIntosh, Marin Andersen

  • 1Cancer Prevention Research Program, Public Health Sciences, Fred Hutchinson Cancer Research Center, MP-900, 1100 Fairview Avenue North, Seattle, WA 98109-1024, USA. nurban@fhcrc.org

Hematology/Oncology Clinics of North America
|September 10, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differences in overall survival for invasive epithelial ovarian cancer by race and ethnicity: results from the Ovarian Cancer Association Consortium.

British journal of cancer·2026
Same author

En-Do's and En-Don'ts: Navigating the rapidly evolving clinical landscape in endometrial cancer.

Gynecologic oncology·2026
Same author

Molecular and spatial differences in the tumor microenvironment of high-grade serous ovarian cancers with short versus long-term survival.

Gynecologic oncology·2026
Same author

Are patient factors associated with real-world antibody-drug conjugate outcomes in gynecologic cancers?

Gynecologic oncology·2026
Same author

Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma.

Nature communications·2026
Same author

Genome-wide classification of tumor-derived reads from bulk long-read sequencing.

bioRxiv : the preprint server for biology·2026
Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026
Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026
See all related articles

Developing effective ovarian cancer screening involves optimizing current tests and evaluating new serum markers. Combining multiple markers longitudinally with advanced algorithms improves detection accuracy in diverse populations.

Area of Science:

  • Oncology
  • Biomarker Discovery
  • Medical Diagnostics

Background:

  • Current ovarian cancer screening methods, CA 125 and transvaginal sonography, require optimization.
  • New serum biomarkers like mesothelin and HE4 show promise for improved detection.

Purpose of the Study:

  • To enhance the efficacy and cost-effectiveness of ovarian cancer screening.
  • To evaluate the performance of multimodal screening strategies and novel biomarkers.

Main Methods:

  • Optimizing and combining existing tests (CA 125, transvaginal sonography) in a multimodal approach.
  • Developing and evaluating new serum markers (mesothelin, HE4).
  • Utilizing a parametric empirical Bayes approach for longitudinal marker analysis and incorporating patient/cancer characteristics.

Related Experiment Videos

Main Results:

  • Improved detection rates observed when using multiple serum markers longitudinally.
  • The parametric empirical Bayes approach enhances screening algorithms by accounting for marker stability in heterogeneous populations.
  • Receiver operating characteristic curves are used to evaluate marker sensitivity and specificity.

Conclusions:

  • Multimodal ovarian cancer screening strategies, combining optimized existing tests with novel serum markers analyzed longitudinally, show improved detection potential.
  • Advanced statistical approaches and consideration of individual patient and cancer characteristics are crucial for accurate biomarker evaluation.
  • Ongoing large-scale randomized controlled trials are essential to validate the performance of these enhanced screening methods.